Advertisement
 
YOU ARE HERE: LAT HomeCollectionsBiomerica Inc
IN THE NEWS

Biomerica Inc

FEATURED ARTICLES
BUSINESS
April 15, 2000
The Newport Beach medical technology company reported a net loss of $886,262, or 20 cents a share, for the third quarter ended Feb. 29, compared with a year-earlier net loss of $170,415, or 4 cents a share. Sales remained at $1.8 million.
ARTICLES BY DATE
BUSINESS
April 25, 2001
The Newport Beach medical technology company said it lost $513,845, or 11 cents a share, for its fiscal third-quarter, compared with a net loss of $886,262, or 20 cents a share, for the corresponding period last year. Sales for the quarter ended Feb. 28 were up 28% to $2.3 million.
Advertisement
BUSINESS
July 2, 1999
Francis R. Cano was elected to the board of directors of Biomerica Inc. in Newport Beach. Cano helped develop a $500-million vaccine business at Lederle Laboratories, a division of American Cyanamid Co., and was president and chief operating officer of Aviron in Mountain View, a biotechnology company.
BUSINESS
March 20, 2001 | Dow Jones
Biomerica Inc., a Newport Beach medical technology company, said Monday it will market its 10-minute prostate cancer test to hospitals and physicians in Japan through Nihon Schering, a unit of Schering AG. Financial terms were not disclosed. Biomerica said last week that Japanese regulators approved the sale of its EZ-PSA test, which detects elevated levels of prostate-specific antigen, an early warning indicator of prostate cancer.
BUSINESS
January 17, 1999
Biomerica Inc., a Newport Beach manufacturer of medical diagnostic products, reported a loss of $6,140 for the second quarter ended Nov. 30, contrasted with net income of $28,435, or 1 cent a share, for the same period in 1997. Revenue declined 15% to $2.2 million, from $2.6 million.
BUSINESS
March 13, 2001
Biomerica Inc., a Newport Beach medical technology company, said Monday that the Japanese Ministry of Health has approved the company's disposable prostrate cancer screening test for distribution and marketing. The company said in a press release that the 10-minute test is designed to detect elevated blood levels of prostate specific antigen, an early warning indicator of prostate cancer.
BUSINESS
September 15, 2000
Biomerica Inc., a Newport Beach medical technology company, said it lost $3.9 million, or 86 cents a share, for its fiscal year ended May 31, compared with a year-earlier net loss of $72,548, or 2 cents a share. Revenue fell 8% to $8 million. The company did not break out fourth-quarter results.
BUSINESS
August 17, 2000 | Dow Jones
Biomerica Inc. said it has developed a test that helps detect and monitor the presence of peptic ulcers and stomach cancer. The Newport Beach medical technology company said the test measures the amounts of Pepsinogen-1 present in human serum, which can mark the presence of a peptic ulcer. The test can also be used to measure the effectiveness of treatments.
BUSINESS
March 22, 2000 |
Biomerica Inc., a Newport Beach maker of medical diagnostic products, said Tuesday it signed a two-year exclusive agreement with Sentinel CH, an Italian medical diagnostic product distributor, to market and distribute Biomerica's Allerquant Med90 food allergy kit in Italy. Financial terms weren't disclosed. Biomerica's stock slipped 6 cents a share to $3.09 in Nasdaq trading.
Los Angeles Times Articles
|